Drugs that contain Etelcalcetide

1. List of Parsabiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8999932 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Feb, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in